By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Cascadian Therapeutics (Formally known as Oncothyreon) 

2601 Fourth Avenue
Suite 500
Seattle  Washington  98121   U.S.A.
Phone: 206-801-2100 Fax: 206-801-2101


SEARCH JOBS


Industry
Biotechnology






Company News
Cascadian Therapeutics (ONTY) Amends HER2CLIMB Phase 2 Trial Of Tucatinib In Metastatic HER2-Positive Breast Cancer To Support Registration 12/8/2016 9:38:01 AM
With a New Name and Leader, Cascadian Therapeutics (ONTY) Rejigs Breast Cancer Study to Meet FDA's Standards 12/7/2016 5:55:50 AM
Cascadian Therapeutics (ONTY) Strengthens Management Team With Key Hires, Monique M. Greer And Marc C. Chamberlain, M.D. 11/28/2016 7:10:07 AM
Cascadian Therapeutics (ONTY) Announces Stockholders And Board Of Directors Approve Reverse Stock Split 11/28/2016 7:08:25 AM
Cascadian Therapeutics (ONTY) Reports Third Quarter 2016 Financial Results And Provides Corporate Update 11/8/2016 7:34:22 AM
Cascadian Therapeutics (ONTY) Announces Presentation Of Tucatinib In Combination Therapy In Patients With Cutaneous HER2+ Metastatic Breast Cancer 10/10/2016 8:20:38 AM
Cascadian Therapeutics (ONTY) Announces Proposal For Reverse Stock Split 10/5/2016 7:47:11 AM
Cascadian Therapeutics (ONTY) Announces Poster Presentations On Tucatinib At The European Society Of Medical Oncology (ESMO) 2016 Congress 9/28/2016 7:30:23 AM
Cascadian Therapeutics (ONTY) To Present At The Rodman & Renshaw 18th Annual Global Investment Conference 9/6/2016 8:33:32 AM
Cascadian Therapeutics (ONTY) Announces Approval Of Nonproprietary Name “Tucatinib” For Lead Product Candidate ONT-380 9/1/2016 7:57:02 AM
12345678910...
//-->